Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. (Symbol: XERS) is a pioneering biopharmaceutical company committed to developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company's mission is to revolutionize patient care by creating ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices.
Xeris has successfully brought three groundbreaking products to market:
- Gvoke: A ready-to-use liquid glucagon designed to treat severe hypoglycemia, providing a critical solution for diabetic patients.
- Keveyis: The first FDA-approved therapy for primary periodic paralysis, offering relief for those suffering from this rare genetic disorder.
- Recorlev: Approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome, addressing a previously unmet need in this patient population.
In addition to these commercial successes, Xeris continues to innovate with a robust pipeline of development programs. Utilizing its proprietary formulation technologies, XeriSol and XeriJect, the company aims to bring new therapies to market that ease the administration and increase the efficacy of injectable treatments.
Financially, Xeris Biopharma Holdings has shown significant growth and resilience in a competitive market. Their strategic partnerships and collaborations further bolster their developmental and commercial capabilities, ensuring a steady pipeline of innovative products aimed at improving patient outcomes.
Recent achievements and ongoing projects underline Xeris' commitment to enhancing the quality of life for millions of patients globally. Keep up with the latest updates and news about Xeris Biopharma Holdings, Inc. to stay informed about their ongoing advancements and performance in the biopharmaceutical industry.
Xeris Biopharma Holdings (NASDAQ: XERS) has received a new patent (US Patent Number 11,590,205) from the U.S. Patent and Trademark Office, covering formulations within its Gvoke® product line for treating hypoglycemia. This patent reinforces Xeris' intellectual property strategy, bolstering its XeriSol™ platform. The company boasts a robust patent portfolio of 178 patents globally, with 33 issued in the U.S., and additional applications pending. The CEO, Paul R. Edick, emphasized the significance of this patent in enhancing the company’s market position. Xeris is committed to developing innovative therapies, with existing products including Gvoke®, Keveyis®, and Recorlev®, and a diverse pipeline aimed at various human diseases.
Xeris Biopharma Holdings (Nasdaq: XERS) has entered a collaboration with Regeneron Pharmaceuticals to utilize its XeriJect™ platform for developing concentrated subcutaneous injections of two undisclosed monoclonal antibodies. The agreement includes an upfront payment and potential milestone payments based on preclinical achievements. Regeneron retains the option to commercially license the Xeris technology and nominate additional molecules for reformulation. XeriJect™ offers ready-to-use, high-drug-loaded suspensions, addressing patient needs in drug delivery. This partnership is a part of Xeris' ongoing collaborations with major biopharmaceutical firms.
Xeris Biopharma Holdings (Nasdaq: XERS) appointed Ricki Fairley to its Board of Directors, expanding the board to nine members as of March 27, 2023. Fairley brings over 35 years of marketing experience, including roles at Johnson & Johnson and Coca-Cola. She is the co-founder and CEO of TOUCH, The Black Breast Cancer Alliance and has a history of advocating for increased participation of Black women in clinical trials. The company's focus remains on developing and commercializing innovative products to enhance patient care.
FAQ
What is the current stock price of Xeris Biopharma Holdings (XERS)?
What is the market cap of Xeris Biopharma Holdings (XERS)?
What does Xeris Biopharma Holdings, Inc. specialize in?
What are the main products of Xeris Biopharma?
What is Gvoke used for?
What makes Xeris' therapies unique?
What proprietary technologies does Xeris use?
How many products has Xeris successfully commercialized?
What is Keveyis used for?
What is Recorlev approved to treat?
What are XeriSol and XeriJect?
Where can I find the latest news about Xeris Biopharma Holdings?
